ProCE Banner Activity

Expert Guidance in Heart Failure: Closing the Gap in SLGT2 Inhibitor Evidence vs Use

Clinical Thought

Although the implementation and uptake of SGLT2 inhibitors across the heart failure spectrum are not optimized, learn why guidelines recommend these therapies and how you can improve patient outcomes through the effective use of these agents.

Released: April 24, 2025

Expiration: April 23, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

Boehringer Ingelheim Pharmaceuticals, Inc.

Eli Lilly and Company

Disclosure

Primary Author

Javed Butler, MD, MPH, MBA: consultant/advisor/speaker: Abbott, Adaptyx, American Regent, Amgen, Applied Therapeutics, AskBio, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, Cardior, CSL Behring, CVRx, Cytokinetics, Edwards, Faraday, Imbria, Impulse Dynamics, Innolife, Inventiva, Lexicon, Lilly, Medtronics, Merck, Owkin, Novartis, Novo Nordisk, Pharmacosmos, PharmaIN, Prolaio, Regeneron, Renibus, Roche, Secretome, Vifor, Zoll.